NeuroX1 is developing a target ID and drug discovery platform leveraging proprietary generative AI algorithms to create the next generation of therapeutics for neurological disorders. Our early-stage pipeline consists of several pre-clinical assets partnered with a variety of pharma companies and institutions.
Company Details
- Employees
- 4
- Founded
- 2021
- Address
- Austin, Tx 78705, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.neurox1.com
- Keywords
- generative drug discovery, biotechnology, neurology, neurodegenerative, rare disease, pediatric rare disease, AI, neuroscience, cancer, brain, generativeAI, Alzheimer's, Parkinson's, preclinical, MS, big pharma, partnerships, target ID, generative drugs, novel drugs, novel small molecules, future of drug discovery, inhibitors, neurosurgery, neural networks, platform technology, drug discovery platform, computational chemistry, computational biology, target discovery.
- HQ
- Austin, TX
Neurox1 Inc. Questions
Neurox1 Inc.'s website is https://www.neurox1.com
Neurox1 Inc.'s LinkedIn profile is https://www.linkedin.com/company/neurox1
Neurox1 Inc. has
4 employees.
View email and phone details for 4
employees at Neurox1 Inc..
Neurox1 Inc.'s industry is
Biotechnology Research
Neurox1 Inc.'s top competitors are
Elligo Health Research,
Paradromics,
Veritas Innovation,
Precigenetics,
Vibe Capital,
Natera,
Neurobane,
Grey Rock Investment Partners,
Everlume Bio,
To Cure A Rose Foundation.
Neurox1 Inc.'s categories are Biotechnology Research
Neurox1 Inc.'s founding year is 2021
